Friday’s jobs report could bolster the view that the American economy is holding steady, but an oil price shock could ...

The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...

The company has been doing incredibly well, and revenue as well as profits have skyrocketed in recent quarters. Shares of ...

The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 ...

Fox News' Bryan Llenas reports from the picket line at Red Hook Terminal in New York on the union's demands and impact of the ...

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

Hims & Hers' (HIMS) stock drop marks the latest overhang on a company that has more than doubled in value over the past 12 ...

Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration said Eli Lilly's popular weight-loss drugs ...

The S&P 500 Index ( $SPX) ( SPY) today is down by -0.38%, the Dow Jones Industrials Index ( $DOWI ) ( DIA) is down by -0.66%, and the Nasdaq 100 Index ( $IUXX) ( QQQ) is down by -0.25%.

Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed ...

The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...

The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...